Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib - 14/09/17
, Camelia S. Sima, MD, MS b, Natalia Sadetsky, MD, PhD b, Jeannie Hou, MD b, Ivor Caro, MD b, Mary-Margaret Chren, MD a, Sarah T. Arron, MD, PhD aAbstract |
Background |
Vismodegib is a first-in-class agent targeting the hedgehog signaling pathway for treatment of patients with locally advanced basal cell carcinoma (BCC) and metastatic BCC. There have been concerns about the development of squamous cell carcinoma (SCC) in patients treated with this drug.
Objective |
We sought to determine whether treatment with vismodegib is associated with an increase in the risk of cutaneous SCC.
Methods |
In this retrospective cohort study, patients treated with vismodegib as part of phase I and II clinical studies were compared with participants from the University of California, San Francisco, Nonmelanoma Skin Cancer Cohort who received standard therapy for primary BCC. In total, 1675 patients were included in the analysis, and the development of SCC after vismodegib exposure was assessed.
Results |
The use of vismodegib was not associated with an increased risk of subsequent development of SCC (adjusted hazard ratio, 0.57; 95% confidence interval, 0.28-1.16). Covariates including age, sex, history of previous nonmelanoma skin cancer, and number of visits per year were significantly associated with the development of SCC.
Limitations |
A limitation of the study was that a historic control cohort was used as a comparator.
Conclusions |
Vismodegib was not associated with an increased risk of subsequent SCC when compared with standard surgical treatment of BCC.
Le texte complet de cet article est disponible en PDF.Key words : basal cell carcinoma, locally advanced, metastatic, safety, squamous cell carcinoma, vismodegib
Abbreviations used : BCC, BCNS, laBCC, mBCC, NMSC, SCC
Plan
| This study was supported in part by Genentech/Roche. Genentech/Roche was not involved in the design and conduct of the study. Genentech/Roche was not involved in the collection, management, analysis and interpretation of data. Genentech/Roche was involved in the preparation, review, or approval of the manuscript. Genentech/Roche was involved in the decision to submit the manuscript for publication. |
|
| Conflicts of interest: Dr Chren was a consultant for Genentech from 2012-2013 for patient-reported outcomes. Drs Caro, Sadetsky, Sima, and Hou are employees of Genentech/Roche and hold stock and stock options in Genentech/Roche. Dr Arron has been an investigator on Genentech clinical trials related to vismodegib. The remaining authors have nothing to disclose. |
Vol 77 - N° 4
P. 713-718 - octobre 2017 Retour au numéro
Article précédent
- Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation
- Lawrence F. Kuklinski, Shufeng Li, Margaret R. Karagas, Wen-Kai Weng, Bernice Y. Kwong
- Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study
- Aaron R. Mangold, Agnieszka K. Thompson, Mark D. Davis, Ieva Saulite, Antonio Cozzio, Emmanuella Guenova, Emmilia Hodak, Iris Amitay-Laish, Ramon M. Pujol, Mark R. Pittelkow, Robert Gniadecki
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?